Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ANPEP | P15144 | 1/20 | 0.52 |
| ▸ | ENPEP | Q07075 | 1/20 | 0.52 |
| ▸ | SLC6A12 | P48065 | 5/20 | 0.50 |
| ▸ | SLC6A11 | P48066 | 5/20 | 0.50 |
| ▸ | SLC6A13 | Q9NSD5 | 5/20 | 0.50 |
| ▸ | SLC6A1 | P30531 | 2/20 | 0.50 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.50 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.50 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.50 |
| ▸ | GABRR1 | P24046 | 1/20 | 0.50 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | PLG | P00747 | 1/20 | 0.38 |
| ▸ | PLAT | P00750 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.36 |
| ▸ | DGAT1 | O75907 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL229034 | 1.00 | ANPEP (0.52) | ANPEPENPEPSLC6A12SLC6A11SLC6A13 | |
| SCHEMBL200897 | 1.00 | ANPEP (0.52) | ANPEPENPEPSLC6A12SLC6A11SLC6A13 | |
| Hydrochloric Acid SCHEMBL2993122 | 0.98 | ANPEP (0.50) | ANPEPENPEPSLC6A12SLC6A11SLC6A13 | |
| Hydrochloric Acid SCHEMBL2993124 | 0.98 | ANPEP (0.50) | ANPEPENPEPSLC6A12SLC6A11SLC6A13 | |
| Hydrochloric Acid SCHEMBL4276196 | 0.98 | ANPEP (0.50) | ANPEPENPEPSLC6A12SLC6A11SLC6A13 | |
| SCHEMBL3542706 | 0.93 | ANPEP (0.47) | ANPEPENPEPSLC6A12SLC6A11SLC6A13 | |
| SCHEMBL3542704 | 0.93 | ANPEP (0.47) | ANPEPENPEPSLC6A12SLC6A11SLC6A13 | |
| Sulfuric Acid SCHEMBL7803541 | 0.91 | ANPEP (0.46) | ANPEPENPEPSLC6A12SLC6A11SLC6A13 | |
| Sulfuric Acid SCHEMBL4208349 | 0.91 | ANPEP (0.46) | ANPEPENPEPSLC6A12SLC6A11SLC6A13 | |
| SCHEMBL24483431 | 0.87 | ANPEP (0.56) | ANPEPENPEPSLC6A12SLC6A11SLC6A13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 67 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2019011879-A1 | THERAPEUTIC FOR TREATING CAPILLARY LEAK SYNDROME | HENNING RAINER (CH) | 2019-01-17 | — | — | WO | claimed |
| US-8088890-B2 | Peptides and peptidomimetic compounds, the manufacturing thereof as well as their use for preparing a therapeutically and/or preventively active pharmaceutical composition | FIBREX MEDICAL RESEARCH & DEVELOPMENT GMBH (AT) | 2012-01-03 | — | — | US | claimed |
| EP-2334324-A2 | BBETA (15-42) AND ITS ANALOGUES COMBINED WITH CYCLOSPORINE FOR TREATMENT OF REPERFUSION INJURY | Fibrex Medical Research & Development GmbH (AT) | 2011-06-22 | — | — | EP | claimed |
| EP-2274328-A1 | PEPTIDES, PEPTIDOMIMETICS AND DERIVATIVES THEREOF, THE MANUFACTURING THEREOF AS WELL AS THEIR USE FOR PREPARING A THERAPEUTICALLY AND/OR PREVENTIVELY ACTIVE PHARMACEUTICAL COMPOSITION | Fibrex Medical Research & Development GmbH (AT) | 2011-01-19 | — | — | EP | claimed |
| WO-2010043972-A2 | PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE FOR THE PREVENTION AND TREATMENT OF HYPOXIC INJURY | FIBREX MEDICAL RESEARCH & DEVELOPMENT GMBH (AT) | 2010-04-22 | — | — | WO | claimed |
| US-20100081787-A1 | PEPTIDES AND PEPTIDOMIMETIC COMPOUNDS, THE MANUFACTURING THEREOF AS WELL AS THEIR USE FOR PREPARING A THERAPEUTICALLY AND/OR PREVENTIVELY ACTIVE PHARMACEUTICAL COMPOSITION | FIBREX MEDICAL RESEARCH & DEVELOPMENT GMBH (AT) | 2010-04-01 | — | — | US | claimed |
| WO-2009137850-A1 | PEPTIDES, PEPTIDOMIMETICS AND DERIVATIVES THEREOF, THE MANUFACTURING THEREOF AS WELL AS THEIR USE FOR PREPARING A THERAPEUTICALLY AND/OR PREVENTIVELY ACTIVE PHARMACEUTICAL COMPOSITION | FIBREX MEDICAL RESEARCH & DEVELOPMENT GMBH (AT) | 2009-11-19 | — | — | WO | claimed |
| EP-1828240-B1 | NOVEL MULTIMERIC CD40 LIGANDS, METHOD FOR PREPARING SAME AND USE THEREOF FOR PREPARING DRUGS | CENTRE NAT RECH SCIENT (FR) | 2009-07-29 | — | — | EP | claimed |
| EP-1296718-A1 | PHARMACEUTICAL COMPOSITION OF MODIFIED PNA MOLECULES | Pantheco A/S (DK) | 2003-04-02 | — | — | EP | claimed |
| WO-2001076636-A2 | PHARMACEUTICAL COMPOSITION OF MODIFIED PNA MOLECULES | PANTHECO A/S (DK) | 2001-10-18 | — | — | WO | claimed |
| EP-4153310-B1 | BBETA-15-42 FOR THE TREATMENT OF VIRAL ENDOTHELITIS | F4 PHARMA GMBH (AT) | 2026-02-18 | — | — | EP | disclosed |
| US-20230293640-A1 | COMPOUNDS FOR THE TREATMENT OF ENDOTHELIITIS IN CONTEXT OF VIRALLY CAUSED DISEASES | F4 PHARMA GMBH (AT) | 2023-09-21 | — | — | US | disclosed |
| CN-116348128-A | Bβ15-42 for treating viral endopdermatitis | F4医药有限责任公司 | 2023-06-27 | — | — | CN | disclosed |
| EP-4153310-A1 | BBETA-15-42 FOR THE TREATMENT OF VIRAL ENDOTHELITIS | F4 Pharma GmbH (AT) | 2023-03-29 | — | — | EP | disclosed |
| US-20220226484-A1 | THERAPEUTIC PEPTIDES | COHBAR, INC. | 2022-07-21 | — | — | US | disclosed |
| WO-2008151434-A1 | SMALL CATIONIC ANTIMICROBIAL PEPTIDES | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2008-12-18 | — | — | WO | disclosed |
| WO-2008022444-A1 | SMALL CATIONIC ANTIMICROBIAL PEPTIDES | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2008-02-28 | — | — | WO | disclosed |
| WO-2003092736-A2 | PEPTIDE NUCLEIC ACID CONJUGATES WITH TRANSPORTER PEPTIDES | PANTHECO A/S (DK) | 2003-11-13 | — | — | WO | disclosed |
| EP-1296718-A1 | PHARMACEUTICAL COMPOSITION OF MODIFIED PNA MOLECULES | Pantheco A/S (DK) | 2003-04-02 | — | — | EP | disclosed |
| WO-2001076636-A2 | PHARMACEUTICAL COMPOSITION OF MODIFIED PNA MOLECULES | PANTHECO A/S (DK) | 2001-10-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230293640-A1 | COMPOUNDS FOR THE TREATMENT OF ENDOTHELIITIS IN CONTEXT OF VIRALLY CAUSED DISEASES | FGB, SERPINC1, ECE1 | ANPEP 79/4885ENPEP 34/4885SLC6A12 3555/4885 |
| US-20100081787-A1 | PEPTIDES AND PEPTIDOMIMETIC COMPOUNDS, THE MANUFACTURING THEREOF AS WELL AS THEIR USE FOR PREPARING A THERAPEUTICALLY AND/OR PREVENTIVELY ACTIVE PHARMACEUTICAL COMPOSITION | NGLY1, GHRHR, GHSR | ANPEP 161/4885ENPEP 635/4885SLC6A12 3796/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.